2011

A Personal Beginning

Virta co-founder and CEO Sami Inkinen wins his age group at the Ironman 70.3 World Championships and finds out he has prediabetes that same year.

Unsatisfied with the conventional wisdom of “exercise more and eat less,” Sami digs into the science of type 2 diabetes, leading him to Drs. Stephen Phinney and Jeff Volek, renowned experts on the science of carbohydrate restriction and metabolic health.

A Personal Beginning

2014

Virta is Born

With the consultation from Steve and Jeff on using nutritional ketosis for athletic performance, Sami and his wife Meredith complete a record-breaking row from San Francisco to Hawaii to bring awareness to nutrition’s impact on our health.

Sami, Steve, and Jeff join forces, combining Steve and Jeff’s scientific knowledge with Sami’s technology expertise and Virta Health is born. Our mission—to reverse type 2 diabetes in 100M people by 2025.

2015—2016

A Commitment to Science and Evidence

Virta’s clinical trial is kicked-off in West Lafayette, Indiana, establishing the scientific foundation for type 2 diabetes reversal and Virta’s unwavering commitment to being evidence-based.

Virta later launches publicly to coincide with the release of our first peer-reviewed manuscript, which demonstrated diabetes reversal in nearly half of our population in as little as 10 weeks. 87% of patients on insulin either reduced usage or eliminated it altogether.

A commitment to science and evidence

2017

Team Building and Care Model Innovation

Virta establishes an advisory board of eminent physicians, scientists, and policy makers. Dr. Don Berwick, former Administrator of the Centers for Medicare and Medicaid Services, joins Virta's Board of Directors.

Meanwhile, we refine our continuous remote care model, upending traditional diabetes treatment by providing near real-time and technology-enabled access to medical providers and health coaches. The Virta Treatment is expanded to every state in the nation.

NGrowth, Team Building, and Technology

2018

Sustainable Type 2 Reversal and Cardiovascular Benefits

Virta’s 1-year peer-reviewed results how diabetes reversal in 60% of completing patients, with 94% of participants reducing or eliminating insulin usage.

We release another peer-reviewed paper on the cardiovascular benefits of the Virta Treatment, which showed significant improvement in 22 of 26 markers of cardiovascular disease risk in patients with T2D.

Performance-based Fees and Growth

On the heels of a $45M Series B funding, doubling our team size, and 3x growth in customers, Virta announces that we’ll put 100% of our fees at risk for our enterprise partners, accelerating adoption of the Virta Treatment and bringing diabetes reversal to as many people as possible.

One Year Outcomes

60%

Participants achieving diabetes reversal

94%

Participants reducing or eliminating insulin usage

12%

Average weight loss (30 lbs) among participants

Data represents participants enrolled at one year

2025

Virta revolutionizes healthcare by proving chronic disease is reversible in hundreds of millions of people

So much of our story is still untold, and we’re looking forward to the journey on our way to reversing type 2 diabetes in 100 million people by 2025.

Our Investors


Venrock
Creandum
Obvious
Caffeinated Capital
SciFi VC
Founders Fund
Playground

Scientific Advisors


Bruce Bistrian, MD, PhD

Chief, Clinical Nutrition, Beth Israel Deaconess Medical Center and Professor of Medicine at Harvard Medical School. Dr. Bistrian is also the Chairman of the Executive Committee of the Division of Nutrition at Harvard.


Fredrick Hecht, MD

Osher Foundation Endowed Chair in Research in Integrative Medicine and a Professor of Medicine at the University of California San Francisco. He is also Research Director of the Osher Center for Integrative Medicine.


Ronald M. Krauss, MD

Senior Scientist and Director of Atherosclerosis Research at Children's Hospital Oakland Research Institute, Adjunct Professor of Medicine at UCSF, and Adjunct Professor of Nutritional Sciences at UC Berkeley.


Carol Levy, MD

Director of the Mount Sinai Diabetes Center and an Associate Professor of Medicine and Endocrinology, Diabetes and Bone Disease at Mount Sinai Hospital in New York.


Ethan Weiss, MD

Cardiologist specializing in preventive cardiology, coronary artery disease and general cardiology. He is an Associate Professor of Medicine at the University of California San Francisco and a member of the Cardiovascular Research Institute (CVRI).


Kevin Fontaine

Chair of the Department of Health Behavior, School of Public Health at the University of Alabama at Birmingham. A psychologist specializing in the treatment of obesity, he is also Adjunct Faculty in Rheumatology and Public Health at Johns Hopkins University.

Industry Advisors


Peter Attia, MD

Founder of Attia Medical, PC, a medical practice with offices in San Diego and New York City, focusing on the applied science of longevity and optimal performance.


Senator Bob Kerrey

Former Governor and Senator of Nebraska. Currently a Managing Director of Allen & Company LLC, the lead financial advisor to Virta Health.


Zeev E. Neuwirth, MD

Senior Medical Director of Population Health for the Carolinas Healthcare System (CHS) since November 2016. In this newly created position within CHS, he serves as the senior most physician responsible for advancing the system's value focused strategies.


Robert E. Ratner, MD, FACP, FACE

Former Chief Scientific & Medical Officer for the American Diabetes Association, the nation’s largest voluntary health organization leading the fight to Stop Diabetes® from 2012-2017.


Michael E. Chernew, PhD

Leonard D. Schaeffer Professor of Health Care Policy and the director of the Healthcare Markets and Regulation (HMR) Lab in the Department of Health Care Policy at Harvard Medical School.


Mark D. Smith, MD, MBA

Professor of Clinical Medicine at the University of California at San Francisco and Visiting Professor at the School of Public Health at the University of California at Berkeley.


Shawn Leavitt

SVP of Total Rewards for Comcast, one of the world’s largest media and technology companies, including Comcast Cable, NBCUniversal and Spectacor. In this role, Shawn and his team are responsible for improving the wellbeing of the company’s 150,000 employees by enhancing their total reward experience and delivering customized products to drive better outcomes.


John Cannon

Former Executive Vice President and Chief Administrative Officer of Health Care Service Corporation, an independent licensee of the Blue Cross Blue Shield Association, which provides health insurance and associated benefits to over 14 million people in Illinois, Texas, Oklahoma, Montana and New Mexico.

Board of Directors & Observers

In addition to Sami Inkinen and Stephen Phinney, we have the support of several other exceptional board participants.


Bob Kocher, MDInvestor

Partner at Venrock and focuses on healthcare IT and services investments. He is a Consulting Professor at Stanford University School of Medicine, Senior Fellow and Advisory Board Member at the Leonard D. Schaeffer Center for Health Policy and Economics at USC, and Guest Scholar at the Brookings Institution Engleberg Center for Health Reform.


Bryan Roberts, PhDObserver

Joined Venrock as a Kauffman Fellow in 1997. He is based in Palo Alto and invests broadly across the healthcare industry. Bryan received his Ph.D. in Chemistry & Chemical Biology from Harvard University. He received his B.A. from Dartmouth College.


Donald M. Berwick, MD, MPP, FRCPDirector

President Emeritus and Senior Fellow at the Institute for Healthcare Improvement (IHI), an organization that Dr. Berwick co-founded and led as President and CEO for 18 years. He is one of the nation's leading authorities on health care quality and improvement. In July, 2010, President Obama appointed Dr. Berwick to the position of Administrator of the Centers for Medicare and Medicaid Services (CMS), which he held until December, 2011.